Literature DB >> 35450193

Comment on: Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.

Dan Călugăru1, Mihai Călugăru1.   

Abstract

Entities:  

Year:  2022        PMID： 35450193      PMCID： PMC8995729          DOI： 10.18240/ijo.2022.04.27

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.779


× No keyword cloud information.
  6 in total

Review 1.  TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations.

Authors:  K Bailey Freund; Jean-François Korobelnik; Robert Devenyi; Carsten Framme; John Galic; Edward Herbert; Hans Hoerauf; Paolo Lanzetta; Stephan Michels; Paul Mitchell; Jordi Monés; Carl Regillo; Ramin Tadayoni; James Talks; Sebastian Wolf
Journal:  Retina       Date:  2015-08       Impact factor: 4.256

2.  Real-world outcomes of two-year Conbercept therapy for diabetic macular edema.

Authors:  Yong Cheng; Li Yuan; Ming-Wei Zhao; Tong Qian
Journal:  Int J Ophthalmol       Date:  2021-03-18       Impact factor: 1.779

3.  Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2018-11-03       Impact factor: 5.258

4.  Classifications of diabetic macular edema.

Authors:  Lee M Jampol
Journal:  Eur J Ophthalmol       Date:  2019-11-26       Impact factor: 2.597

5.  Protective effect of intravitreal bevacizumab and sub-tenon triamcinolone acetonide against occlusion of choriocapillaris induced by photodynamic therapy.

Authors:  Ryo Mukai; Shoji Kishi; Taku Sato; Goro Watanabe; Hidetaka Matsumoto
Journal:  Ophthalmologica       Date:  2010-02-25       Impact factor: 3.250

6.  Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors:  Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal:  J Ocul Pharmacol Ther       Date:  2015-06-03       Impact factor: 2.671
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.